APGE vs. BBIO, BPMC, VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, and NUVL
Should you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.
Apogee Therapeutics vs. Its Competitors
Apogee Therapeutics (NASDAQ:APGE) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.
Apogee Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -524.25%. BridgeBio Pharma's return on equity of 0.00% beat Apogee Therapeutics' return on equity.
Apogee Therapeutics has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500.
79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 42.8% of Apogee Therapeutics shares are owned by insiders. Comparatively, 18.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, BridgeBio Pharma had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 16 mentions for BridgeBio Pharma and 13 mentions for Apogee Therapeutics. BridgeBio Pharma's average media sentiment score of 0.85 beat Apogee Therapeutics' score of 0.60 indicating that BridgeBio Pharma is being referred to more favorably in the news media.
Apogee Therapeutics presently has a consensus target price of $99.00, suggesting a potential upside of 154.63%. BridgeBio Pharma has a consensus target price of $61.20, suggesting a potential upside of 28.25%. Given Apogee Therapeutics' higher probable upside, equities analysts plainly believe Apogee Therapeutics is more favorable than BridgeBio Pharma.
Apogee Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Apogee Therapeutics and BridgeBio Pharma tied by winning 7 of the 14 factors compared between the two stocks.
Get Apogee Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apogee Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:APGE) was last updated on 7/14/2025 by MarketBeat.com Staff
